A Phase II Trial of Bryostatin in Combination With Cisplatin in Patients With Recurrent or Persistent Epithelial Ovarian Cancer

Inclusion Criteria:

- Advanced recurrent or residual ovarian, fallopian tube, or papillary primary
peritoneal cancer which has been histologically confirmed

- Eligible patients include patients with measurable disease who have progressed while
on chemotherapeutic treatment, patients with biopsy-proven persistent,
clinically-measurable disease with best response as stable at the completion of
planned first-line therapy, patients with persistent or recurrent disease with rising
CA-125 to levels at least twice normal; the CA-125 increase must be documented by two
independent measurements; no patient may have received more than two prior regimens
of chemotherapy including first-line treatment

- Patients must have a Karnofsky performance status of greater than or equal to 50% and
an estimated survival of at least three months

- Measured or calculated clearance >= 60 ml/min

- AGC >= 1800/mm^3

- Plts >= 100,000/mm^3

- Bilirubin =< 1.5 mg/dl

- SGOT less than 2 x upper limit of normal

- Previous radiotherapy or chemotherapy must have been completed at least three weeks
before treatment under this protocol

- Patients must have the ability to give voluntary informed consent and to comply with
the treatment and required tests

- Because Bryostatin is of unknown teratogenic potential, women of childbearing
potential must have a negative pregnancy test and must take adequate precautions to
prevent pregnancy during treatment

- Patients with any non-malignant intercurrent illness (e.g. cardiovascular, pulmonary,
or central nervous system disease) which is either poorly controlled with currently
available treatment, or is of such severity that the investigators deem it unwise to
enter the patient on protocol shall be ineligible

- Patients currently being treated for severe infection or who are recovering from
major surgery are ineligible until recovery is deemed complete by the investigator

- The extent of all evaluable and nonevaluable disease must be documented; pretreatment
radiographic examinations should be done no earlier than 4 weeks (28 days) prior to
the first course of chemotherapy; pre-treatment chemistries and CA-125 levels should
be done no earlier than two weeks (14 days) prior to initiation of chemotherapy; (in
calculating days of tests and measurements, the day a test or measurement is done is
considered day 0; therefore, if a test is done on Monday, the Monday four weeks later
would be considered day 28; this allows for efficient patient scheduling without
exceeding the guidelines)